logo-loader
viewArix Bioscience PLC

Arix Bioscience says Harpoon Therapeutics’ IPO pricing range would hike holding value by £4.2mln-£7.9mln

The global healthcare and life science company supporting medical innovation said that increase was compared to the current £20.2mln value of its holding in Harpoon

Life science sign
Arix also said it has indicated an interest in purchasing shares of common stock in Harpoon's public offering

Arix Bioscience PLC (LON:ARIX) noted that further details of proposals by Harpoon Therapeutics Inc. for an underwritten US initial public offering would represent a £4.2mln-£7.9mln increase in the value of its current shareholding in Harpoon.

The LSE main market-listed global healthcare and life science company supporting medical innovation said that increase was compared to the current £20.2mln value of its holding.

READ: Arix Bioscience portfolio firm Harpoon Therapeutics plans US IPO

The UK firm pointed out the figures are based on Harpoon’s amended registration statement, filed with the US Securities and Exchange, which discloses an expected pricing range for the proposed offering of US$13.00–US$15.00 per share.

It noted that the proposed maximum aggregate offering amount specified in the filing is US$93.15mln, which assumes that the public offering price is at the top of the expected pricing range and includes the option that is proposed to be granted to the underwriters to purchase additional shares of common stock.

Arix also said it has indicated an interest in purchasing shares of common stock in the offering, subject to agreement with the underwriters.

Quick facts: Arix Bioscience PLC

Price: 113.5 GBX

LSE:ARIX
Market: LSE
Market Cap: £153.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read